Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Corporate Breaking News

Home : Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Sep 10 2019	Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 10, 2019 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced the presentation of updated phase 1 data for U3-1402, an investigational HER3 targeting antibody drug conjugate (ADC), in 30 patients with...


Source:https://www.prnewswire.com:443/news-releases/updated-phase-1-data-for-daiichi-sankyos-u3-1402-in-patients-with-egfr-mutated-nsclc-presented-at-2019-world-conference-on-lung-cancer-300914515.html

Related News
» Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer » South Korea military says North launches 2 projectiles